
New drug combination increases overall survival in patients with PIK3CA-mutated advanced breast cancer
Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast cancers. A recently completed phase 3 clinical trial, conducted by researchers at Mass General […]